DRD3 and Parkinson disease: More specifically, such behavioral adverse events have previously been documented with the use of dopamine agonist drugs in the treatment of Parkinson’s disease, and agonism at central dopamine D3 receptors, in particular, has been suggested as a potential key mediator in this relationship [83].